Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Venous and arterial thrombosis in patients with VEXAS syndrome

Blood (2024) 143 (21): 2190–2200.

https://doi.org/10.1182/blood.2023022329

Published: 2024

Includes: Supplemental data

Journal Articles

Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis

Blood (2022) 140 (13): 1496–1506.

https://doi.org/10.1182/blood.2022016985

Published: 2022

Includes: Supplemental data

Journal Articles

Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study

Blood (2022) 140 (8): 927–931.

https://doi.org/10.1182/blood.2022016642

Published: 2022

Includes: Supplemental data

Journal Articles

Clinical Efficacy of JAK Inhibitors in Patients with Vexas Syndrome: A Multicenter Retrospective Study

Blood (2021) 138 (Supplement 1): 2608.

https://doi.org/10.1182/blood-2021-150394

Published: 2021

Journal Articles

Somatic Mutations in a Single Residue of UBA1 Cause Vexas, a Severe Adult-Onset Rheumatic Disease Associated with Myeloid Dysplasia

David B. Beck, MDPhD, Zhijie Wu, MD, Bhavisha A Patel, MD, Marcela A Ferrada, MD, Keith A Sikora, MD, Amanda Ombrello, MD, Alina E. Dulau Florea, MD, Weixin Wang, PhD, Emma M. Groarke, MD, Shawn M. Burgess, PhD, Ivona A Aksentijevich, MD, Achim A Werner, PhD, Neal S. Young, MD, Katherine R. Calvo, MD PhD, Daniel L Kastner, MDPhD, Peter C Grayson, MD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-141949

Published: 2020

Journal Articles

Myelodysplasia and Bone Marrow Manifestations of Somatic UBA1 Mutated Autoinflammatory Disease

Ifeyinwa Emmanuela Obiorah, MBBS,PhD, David B. Beck, MDPhD, Weixin Wang, PhD, Amanda Ombrello, MD, Marcela A Ferrada, MD, Zhijie Wu, MD, Keith A Sikora, MD, Megan A Trick, Alina Dulau-Florea, MD, Bhavisha A Patel, MD, Emma Groarke, MD, Shawn M. Burgess, PhD, Achim A Werner, PhD, Ivona A Aksentijevich, MD, Neal S. Young, MD, Daniel L Kastner, MDPhD, Peter C Grayson, MD, Katherine R. Calvo, MD PhD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-140480

Published: 2020

NARROW

Venous and arterial thrombosis in patients with VEXAS syndrome

Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis

Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study

Clinical Efficacy of JAK Inhibitors in Patients with Vexas Syndrome: A Multicenter Retrospective Study

Somatic Mutations in a Single Residue of UBA1 Cause Vexas, a Severe Adult-Onset Rheumatic Disease Associated with Myeloid Dysplasia

Myelodysplasia and Bone Marrow Manifestations of Somatic UBA1 Mutated Autoinflammatory Disease

Email alerts

ASH Publications

American Society of Hematology

Venous and arterial thrombosis in patients with VEXAS syndrome

Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis

Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study

Clinical Efficacy of JAK Inhibitors in Patients with Vexas Syndrome: A Multicenter Retrospective Study

Somatic Mutations in a Single Residue of UBA1 Cause Vexas, a Severe Adult-Onset Rheumatic Disease Associated with Myeloid Dysplasia

Myelodysplasia and Bone Marrow Manifestations of Somatic UBA1 Mutated Autoinflammatory Disease

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only